Back to Search Start Over

Predictors of bowel damage in the long-term progression of Crohn's disease.

Authors :
Fernández-Clotet A
Panés J
Ricart E
Castro-Poceiro J
Masamunt MC
Rodríguez S
Caballol B
Ordás I
Rimola J
Source :
World journal of clinical cases [World J Clin Cases] 2022 Nov 26; Vol. 10 (33), pp. 12208-12220.
Publication Year :
2022

Abstract

Background: Crohn's disease (CD) is a chronic inflammatory bowel disorder that progresses to bowel damage (BD) over time. An image-based index, the Lémann index (LI), has been developed to measure cumulative BD.<br />Aim: To characterize the long-term progression of BD in CD based on changes in the LI and to determine risk factors for long-term progression.<br />Methods: This was a single-center longitudinal cohort study. Patients who had participated in prospective studies on the accuracy of magnetic resonance imaging using endoscopy as a gold standard and who had a follow-up of at least 5 years were re-evaluated after 5-12 years.<br />Results: Seventy-two patients were included. LI increased in 38 patients (52.8%), remained unchanged in 9 patients (12.5%), and decreased in 25 patients (34.7%). The small bowel score and surgery subscale significantly increased ( P = 0.002 and P = 0.001, respectively), whereas the fistulizing subscale significantly decreased ( P = 0.001). Baseline parameters associated with BD progression were ileal location ( P = 0.026), CD phenotype [stricturing, fistulizing, or both ( P = 0.007, P = 0.006, and P = 0.035, respectively)], disease duration > 10 years ( P = 0.019), and baseline LI stricturing score ( P = 0.049). No correlation was observed between BD progression and baseline clinical activity, biological markers, or severity of endoscopic lesions.<br />Conclusion: BD, as assessed by the LI, progressed in half of the patients with CD over a period of 5-12 years. The main determinants of BD progression were ileal location, stricturing/fistulizing phenotype, and disease duration.<br />Competing Interests: Conflict-of-interest statement: Dr. Rimola reports grants from Abbvie, personal fees from Alimentiv, personal fees from Janssen, personal fees from Takeda, non-financial support from Gilead and from Agumab during the conduct of the study.<br /> (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)

Details

Language :
English
ISSN :
2307-8960
Volume :
10
Issue :
33
Database :
MEDLINE
Journal :
World journal of clinical cases
Publication Type :
Academic Journal
Accession number :
36483818
Full Text :
https://doi.org/10.12998/wjcc.v10.i33.12208